Skip to content

Effect of a Butyrate Enema on the Systemic Concentration of Short Chain Fatty Acids

Effect of a Butyrate Enema on the Systemic Concentration of Short Chain Fatty Acids

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02271802
Enrollment
12
Registered
2014-10-22
Start date
2009-06-30
Completion date
2009-11-30
Last updated
2014-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SCFA Metabolism

Keywords

Butyrate, Interorgan metabolism, Short-chain fatty acids, Gut production

Brief summary

In this placebo-controlled randomized parallel study the effects of a butyrate enema on plasma short-chain fatty acids (SCFA) concentrations and fluxes from portal drained viscera, liver and the splanchnic area are investigated

Detailed description

Patients undergoing upper abdominal surgery are included. During surgery they receive a butyrate enema or placebo enema. Before and after rectal administration, plasma samples are taken from several veins and arteries to analyse SCFA concentrations and fluxes from portal drained viscera, liver and the splanchnic area.

Interventions

DIETARY_SUPPLEMENTSodium butyrate

Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.

DIETARY_SUPPLEMENTNaCl

Sponsors

Top Institute Food and Nutrition
CollaboratorOTHER
Maastricht University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients undergoing open liver resection or pancreaticoduodenectomy

Exclusion criteria

* known parenchymal liver disease * presence of ileostomy or colostomy * patients with inflammatory bowel disease * antibiotics, prebiotics or probiotics 2 months prior to surgery

Design outcomes

Primary

MeasureTime frame
Plasma SCFAs0, 5, 15, 30 min after administration

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026